|
FBXO3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.99840144432528E-15 |
| Normal-vs-Stage2 |
1.73110000001309E-06 |
| Normal-vs-Stage3 |
3.99680288865056E-15 |
| Normal-vs-Stage4 |
1.62470037423645E-12 |
| Stage1-vs-Stage2 |
2.134200E-01 |
| Stage1-vs-Stage3 |
3.197500E-02 |
| Stage1-vs-Stage4 |
1.590900E-04 |
| Stage2-vs-Stage3 |
1.404090E-02 |
| Stage2-vs-Stage4 |
1.368880E-04 |
| Stage3-vs-Stage4 |
5.435600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.02799999999836E-05 |
| Normal-vs-Asian |
9.49139999928406E-09 |
| Caucasian-vs-AfricanAmerican |
3.861400E-01 |
| Caucasian-vs-Asian |
2.432000E-01 |
| AfricanAmerican-vs-Asian |
9.931800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-15 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
1.362610E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.85185200507476E-12 |
| Normal-vs-Age(41-60Yrs) |
4.9293902293357E-14 |
| Normal-vs-Age(61-80Yrs) |
1.626032641866E-12 |
| Normal-vs-Age(81-100Yrs) |
1.032620E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.231200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.976240E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.009400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.649230E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.857600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.883800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.056720E-03 |
| Classical-VS-Follicular |
9.942500E-03 |
| Classical-VS-Other |
6.385400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.65804999999741E-05 |
| Tall-VS-Other |
2.940600E-01 |
| Tall-VS-Normal |
1.53210777398272E-14 |
| Follicular-VS-Other |
2.443400E-01 |
| Follicular-VS-Normal |
4.96259999982485E-07 |
| Other-VS-Normal |
7.231300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.65929508916452E-13 |
| Normal-vs-N1 |
9.47020240005259E-14 |
| N0-vs-N1 |
8.258100E-03 |
|
|
